Xenetic Biosciences, Inc.

NasdaqCM:XBIO Stock Report

Market Cap: US$6.1m

Xenetic Biosciences Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Jeff Eisenberg

Chief executive officer

US$632.8k

Total compensation

CEO salary percentage63.9%
CEO tenure6.4yrs
CEO ownershipn/a
Management average tenure6.9yrs
Board average tenure5yrs

Recent management updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Recent updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Xenetic Biosciences reports Q2 results

Aug 12

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Aug 02

Xenetic inks clinical manufacturing contract with Catalent

Jul 07

Xenetic Biosciences reports Q3 results

Nov 13

CEO Compensation Analysis

How has Jeff Eisenberg's remuneration changed compared to Xenetic Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$4m

Sep 30 2023n/an/a

-US$4m

Jun 30 2023n/an/a

-US$4m

Mar 31 2023n/an/a

-US$6m

Dec 31 2022US$633kUS$404k

-US$7m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$750kUS$368k

-US$6m

Sep 30 2021n/an/a

-US$5m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$446kUS$350k

-US$11m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$14m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$603kUS$300k

-US$18m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018US$318kUS$300k

-US$7m

Sep 30 2018n/an/a

-US$1m

Jun 30 2018n/an/a

-US$2m

Mar 31 2018n/an/a

-US$3m

Dec 31 2017US$815kUS$300k

-US$4m

Compensation vs Market: Jeff's total compensation ($USD632.83K) is about average for companies of similar size in the US market ($USD662.11K).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


CEO

Jeff Eisenberg (57 yo)

6.4yrs

Tenure

US$632,827

Compensation

Mr. Jeffrey F. Eisenberg, also known as Jeff, Esq., has been the Chief Executive Officer of Xenetic Biosciences, Inc. since October 26, 2017; has been its Director since July 11, 2016 and also serves as it...


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Eisenberg
CEO, President & Director6.4yrsUS$632.83kno data
James Parslow
CFO, COO & Corporate Secretary6.9yrsUS$473.99k0%
$ 0
Curtis Lockshin
Chief Scientific Officer7.2yrsUS$470.37k0%
$ 0

6.9yrs

Average Tenure

58yo

Average Age

Experienced Management: XBIO's management team is seasoned and experienced (6.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Eisenberg
CEO, President & Director7.7yrsUS$632.83kno data
Adam Logal
Independent Chairman of the Board6.6yrsUS$59.56k0%
$ 0
Roger Kornberg
Independent Director8.1yrsUS$59.56k0%
$ 0
Firdaus Dastoor
Independent Director10.2yrsUS$59.56k0%
$ 0
James Callaway
Independent Director6.6yrsUS$59.56k0%
$ 0
Dmitry Genkin
Non-Executive Directorless than a yearno data4.44%
$ 272.5k
Guenther Koehne
Member of Scientific Advisory Board4.8yrsno datano data
Matthew Frigault
Member of Scientific Advisory Board5.2yrsno datano data
Alexey Vinogradov
Independent Director4.7yrsUS$59.56kno data
Grigory Borisenko
Independent Non-Executive Director4.5yrsUS$59.56k0%
$ 0
Maksim Mamonkin
Member of Scientific Advisory Board4.1yrsno datano data
Allan Tsung
Member of Scientific Advisory Board1.8yrsno datano data

5.0yrs

Average Tenure

56.5yo

Average Age

Experienced Board: XBIO's board of directors are considered experienced (5 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.